Myofibroma in Infancy and Childhood

被引:20
作者
Mahajan, Priya [1 ]
Hicks, John [1 ,2 ]
Chintagumpala, Murali [1 ]
Venkatramani, Rajkumar [1 ]
机构
[1] Texas Childrens Hosp, Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, 6701 Fannin St,Suite 1510-23, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
关键词
fibrous tumors; low-dose chemotherapy; myofibroma; myofibromatosis; GENERALIZED INFANTILE MYOFIBROMATOSIS; AUTOSOMAL-DOMINANT INHERITANCE; THERAPY; CHILDREN; CHEMOTHERAPY; METHOTREXATE; FIBROMATOSIS; VINBLASTINE; INVOLVEMENT; TUMORS;
D O I
10.1097/MPH.0000000000000732
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Myofibromas are rare fibroblastic-myofibroblastic tumors in children. Their biological behavior is unpredictable and spontaneous regressions have been described. This is a retrospective review of clinical characteristics, treatment, and outcome of children diagnosed with myofibroma between 1999 and 2013 at Texas Children's Hospital. The median age at diagnosis of 42 patients was 37 months. Approximately two thirds of the patients were male. The median length of follow-up was 50.5 months (range, 0 to 165 mo). Thirty-eight patients (90%) had solitary lesions; 19 (50%) in the head and neck, 10 (26%) in the limbs, and 9 (24%) in the trunk. Twelve patients underwent a complete surgical resection. Of the 30 patients with positive margins, only 1 had tumor progression. Two patients had multicentric involvement, and 2 patients had generalized disease with visceral involvement. One patient with generalized disease and a progressive maxillary sinus mass was treated with vinblastine and methotrexate chemotherapy followed by complete surgical resection. All patients were alive at last follow-up. Myofibromas of childhood demonstrate clinical variability, and may spontaneously regress. Positive surgical margins do not adversely affect outcome. The rare patient with progressive unresectable disease may benefit from chemotherapy.
引用
收藏
页码:E136 / E139
页数:4
相关论文
共 31 条
[1]   PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib [J].
Arts, F. A. ;
Chand, D. ;
Pecquet, C. ;
Velghe, A. I. ;
Constantinescu, S. ;
Hallberg, B. ;
Demoulin, J-B .
ONCOGENE, 2016, 35 (25) :3239-3248
[2]   Remission of infantile generalized myofibromatosis after interferon alpha therapy [J].
Auriti, Cinzia ;
Kieran, Mark W. ;
Deb, Giovanni ;
Devito, Rita ;
Pasquini, Luciano ;
Danhaive, Olivier .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2008, 30 (02) :179-181
[3]   First-Line Therapy of Generalized Infantile Myofibromatosis With Low-Dose Vinblastine and Methotrexate [J].
Azzam, Raed ;
Abboud, Miguel ;
Muwakkit, Samar ;
Khoury, Nabil ;
Saab, Raya .
PEDIATRIC BLOOD & CANCER, 2009, 52 (02) :308-308
[4]  
BAIRD PA, 1976, CLIN GENET, V9, P488
[5]  
BRACKO M, 1992, CANCER-AM CANCER SOC, V69, P1294
[6]   A Recurrent PDGFRB Mutation Causes Familial Infantile Myofibromatosis [J].
Cheung, Yee Him ;
Gayden, Tenzin ;
Campeau, Philippe M. ;
LeDuc, Charles A. ;
Russo, Donna ;
Van-Hung Nguyen ;
Guo, Jiancheng ;
Qi, Ming ;
Guan, Yanfang ;
Albrecht, Steffen ;
Moroz, Brenda ;
Eldin, Karen W. ;
Lu, James T. ;
Schwartzentruber, Jeremy ;
Malkin, David ;
Berghuis, Albert M. ;
Emil, Sherif ;
Gibbs, Richard A. ;
Burk, David L. ;
Vanstone, Megan ;
Lee, Brendan H. ;
Orchard, David ;
Boycott, Kym M. ;
Chung, Wendy K. ;
Jabado, Nada .
AMERICAN JOURNAL OF HUMAN GENETICS, 2013, 92 (06) :996-1000
[7]  
CHUNG EB, 1981, CANCER-AM CANCER SOC, V48, P1807, DOI 10.1002/1097-0142(19811015)48:8<1807::AID-CNCR2820480818>3.0.CO
[8]  
2-G
[9]   Fibroblastic and Myofibroblastic Tumors in Children and Adolescents [J].
Coffin, Cheryl M. ;
Alaggio, Rita .
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2012, 15 :127-180
[10]   Successful therapy of a patient with infantile generalized myofibromatosis [J].
Day, M ;
Edwards, AO ;
Weinberg, A ;
Leavey, PJ .
MEDICAL AND PEDIATRIC ONCOLOGY, 2002, 38 (05) :371-373